H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback

Exelixis, Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy according to analysts. On August 12, H.C. Wainwright analyst Robert Burns maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL), while trimming the company’s price target from $53 to $46. However, despite the cut, the price target is nearly 21% above the current market price of $38.12.H.C. Wainwright Maintains Buy on Exelixis (EXEL) Despite STELLAR-305 Phase 3 Setback

Burns cited the company’s decision not to go ahead with the Phase 3 portion of the STELLAR-305 trial for the target cut. Phase 3 of Stellar 305 was considered importantbecause it could have been a critical milestone in validating the full system performance, mission-readiness, and scalability of the Stellar 305 platform.

STELLAR-305 is a clinical trial investigating the use of zanzalintinib, an investigational, oral, third-generation tyrosine kinase inhibitor (TKI) being developed by the company, along with pembrolizumab, a medication used in cancer immunotherapy, as an immune checkpoint inhibitor, for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Military Tech Stocks to Buy Now and 10 High Growth Stocks Outside Tech Analysts Are Bullish On.

Disclosure: None.

View Comments